key: cord-0952234-qmo2nnu1
authors: Essa, Hani; Brousas, Sophia; Whybrow‐Hupptaz, Isabel; Salmon, Thomas; Sankaranarayanan, Rajiv
title: What is the effect of lockdown upon hospitalisation because of COVID‐19 amongst patients from a heart failure registry?
date: 2021-09-16
journal: Int J Clin Pract
DOI: 10.1111/ijcp.14425
sha: 0fd7e7b76fe602348a8f5db414226a38f95ad788
doc_id: 952234
cord_uid: qmo2nnu1

nan

To the Editor Coronavirus disease 2019 (COVID-19) is associated with mortality risk in heart failure (HF) patients. 1 In order to curb the spread of the virus, the UK government announced a national lockdown in March 2020. Whilst there is data 2-6 regarding the prognosis of HF patients hospitalised with COVID-19, the impact of lockdown upon in incidence of hospitalisation, is unknown.

Our single centre, retrospective observational study was undertaken in a British university hospital to analyse the effect of lockdown upon COVID-19 hospitalisations amongst HF patients and the predictors of risk. We collated data regarding co-morbidities (Charlson Co-morbidity Index-CCI), 7 Note: Demographic data and background of patients admitted with COVID vs no-COVID P < .05 is taken to mean statistical significance.

Abbreviations: ACEI, Angiotensin heart receptor enzyme inhibitor; AF, Atrial fibrillation; ARB, Angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; BMI, Body mass index; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; GWTG, Get with the guidelines risk score; HF, Heart failure; HFpEF, heart failure with preserved ejection fraction; HTN, hypertension; IHD, ischemic heart disease.

We identified 1097 HF patients from our existing HF registry with HF hospitalisation in 2018 and 2019. Fifty out of 801 (6.2%) surviving HF patients required hospitalisation because of COVID-19 from March to November 2020 (COVID group); 24 patients (3.1%) during the first lockdown (March-June 2020) and 26 (3.5%) in the post-lockdown period (July-November 2020); P = .7. In comparison to patients not hospitalised with COVID-19 (no-COVID group), the COVID group had a significantly higher prevalence of co-morbidities (Table 1 ) -hypertension (P < .001), diabetes (P = .005), ischaemic heart disease (P = .01) and increased body mass index (P = .04). This data is in line with other studies. 1, 4, 8, 9 CCI was also significantly higher in the COVID group (6.5 ± 1.5 vs no-COVID group 5.7 ± 1; P < .001). The COVID group was frailer (Rockwood CFS in COVID group 6.5 ± 1.5 vs. 6.1 ± 1.1 in no-COVID group; P = .02). HF patients hospitalised with COVID had a longer hospital stay than for HF (median 14.5 days vs 8 days; P < .001) and 30-day mortality was 52%. Study limitations include the single centre, retrospective observational design and relatively small number of COVID-19 hospitalisations in this cohort.

In conclusion, our data suggest that lockdown did not seemingly affect the incidence of amongst patients from our HF registry. Co-morbidity and frailty scores should be incorporated during the initial clinical assessment to aid risk prediction for 30-day mortality.

The authors declared no conflict of interest.

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. 

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy

Prognostic impact of prior heart failure in patients hospitalized with COVID-19

The effect of concomitant COVID-19 infection on outcomes in patients hospitalized with heart failure

Patients perspective on the effect of COVID-19 on heart failure admissions

Manifestation of cardiac injury in hospitalised patients with COVID-19

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Impact of COVID-19 on inpatient referral of acute heart failure: a single-centre experience from the south-west of the UK. ESC

Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19

Report 41 -The 2020 SARS-CoV-2 epidemic in England: key epidemiological drivers and impact of interventions. @imperialcollege

The impact of COVID-19 on the management of heart failure: a United Kingdom patient questionnaire study